Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure Tirzepatide is associated with a much lower all-cause mortality rate than semaglutide when patients present with type 2 diabetes, chronic kidney disease (CKD) and heart failure, according to new data presented at SCAI 2025 Scientific Sessions, the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI)
Mechanistically, podocyte-specific LONP1 deficiency induces mitochondrial homeostasis imbalance and dysfunction, leading to podocyte injury and glomerulosclerosis [121]
However, the causes of infertility in women with mild endometriosis remain unclear and are subject to numerous speculations, mainly relating to endocrine abnormalities, immune disorders, oxidative stress, and aberrant gene expression [8, 9]
Fact: Formulation matters